CHRS

1.52

2.70% 0.04

Handel nachbörslich: 1.49 -0.03 -1.97%

Coherus Biosciences Inc (CHRS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CHRS? Forum Prognose

Schlusskurs vom Vortag:

$1.48

Offen:

$1.44

24-Stunden-Volumen:

4.11M

Relative Volume:

0.80

Marktkapitalisierung:

$175.12M

Einnahmen:

$257.24M

Nettoeinkommen (Verlust:

$-237.89M

KGV:

-0.4578

EPS:

-3.32

Netto-Cashflow:

$-175.17M

1W Leistung:

-5.59%

1M Leistung:

+38.18%

6M Leistung:

-6.17%

1J Leistung:

-21.65%

1-Tages-Spanne:

$1.40

$1.54

1-Wochen-Bereich:

$1.40

$1.75

52-Wochen-Spanne:

$0.6603

$3.70

Coherus Biosciences Inc Stock (CHRS) Company Profile

Firmenname

Coherus Biosciences Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

(650) 649-3530

Adresse

C/O DENNIS M. LANFEAR, REDWOOD CITY, CA

Mitarbeiter

235

Twitter

@coherus_bio

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

CHRS's Discussions on Twitter

Vergleichen Sie CHRS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CHRS Coherus Biosciences Inc	1.52	175.12M	257.24M	-237.89M	-175.17M	-2.60
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-08-16	Herabstufung	UBS	Buy → Neutral
2023-11-17	Eingeleitet	Robert W. Baird	Outperform
2023-11-08	Herabstufung	Maxim Group	Buy → Hold
2023-07-24	Eingeleitet	Citigroup	Buy
2023-05-01	Eingeleitet	Truist	Buy
2023-03-28	Hochstufung	UBS	Neutral → Buy
2022-06-14	Eingeleitet	UBS	Neutral
2022-03-07	Herabstufung	JP Morgan	Overweight → Neutral
2020-07-16	Eingeleitet	BofA Securities	Neutral
2020-04-17	Eingeleitet	SunTrust	Buy
2019-08-13	Eingeleitet	Mizuho	Buy
2019-08-02	Bestätigt	H.C. Wainwright	Buy
2019-08-02	Bestätigt	Maxim Group	Buy
2019-06-11	Eingeleitet	Barclays	Overweight
2019-05-07	Eingeleitet	H.C. Wainwright	Buy
2018-08-28	Eingeleitet	H.C. Wainwright	Buy
2018-03-09	Bestätigt	Maxim Group	Buy
2017-08-08	Bestätigt	JP Morgan	Overweight
2017-06-13	Bestätigt	Maxim Group	Buy
2017-05-05	Eingeleitet	BMO Capital Markets	Outperform
2016-10-19	Eingeleitet	Robert W. Baird	Outperform
2016-09-07	Eingeleitet	Maxim Group	Buy
2016-07-27	Eingeleitet	Citigroup	Buy
2016-01-20	Eingeleitet	Credit Suisse	Outperform

Alle ansehen

Coherus Biosciences Inc Aktie (CHRS) Neueste Nachrichten

Dec 21, 2024

There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise - Simply Wall St

Dec 21, 2024

Dec 18, 2024

Coherus to Present Final Phase 2 Casdozokitug Combination - GlobeNewswire

Dec 18, 2024

Coherus BioSciences to Present Groundbreaking Cancer Treatment Data at ASCO-GI 2025 - StockTitan

Dec 18, 2024

Dec 16, 2024

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development - Seeking Alpha

Dec 16, 2024

Short Interest in Coherus BioSciences, Inc. (NASDAQ:CHRS) Drops By 7.0% - MarketBeat

Dec 16, 2024

Coherus Biosciences' SWOT analysis: stock faces headwinds amid transition - Investing.com

Dec 16, 2024

Dec 11, 2024

Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat

Dec 11, 2024

Dec 10, 2024

Coherus BioSciences to divest UDENYCA franchise for up to $558.4M - MSN

Dec 10, 2024

Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Disciplined Growth Investors Inc. MN - MarketBeat

Dec 10, 2024

Dec 05, 2024

California-Based Biotech Rallies Strongly Following $558.4M Divestiture - MSN

Dec 05, 2024

Coherus price target raised at Baird on agreement to sell Udenyca - Investing.com Canada

Dec 05, 2024

Coherus BioSciences director Tzoumakas to exit board By Investing.com - Investing.com Canada

Dec 05, 2024

Coherus BioSciences director Tzoumakas to exit board - Investing.com

Dec 05, 2024

Intas acquires Udenyca from Coherus BioSciences in potential $558 million deal - BioProcess Insider

Dec 05, 2024

Coherus BioSciences (FRA:8C5) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com

Dec 05, 2024

CHRS (Coherus BioSciences) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com

Dec 05, 2024

Dec 04, 2024

Coherus Biosciences Announces Board Member Resignation - TipRanks

Dec 04, 2024

Coherus Biosciences' SWOT analysis: stock faces headwinds amid transition By Investing.com - Investing.com Australia

Dec 04, 2024

Latham Watkins Advises Coherus in Divesture of UDENYCA Franchise to Intas Pharmaceuticals - Latham & Watkins LLP

Dec 04, 2024

Accord acquires Coherus’ Udenyca business - The Pharma Letter

Dec 04, 2024

Intas to acquire Coherus’ Udenyca assets for up to $558m - World Pharmaceutical Frontiers

Dec 04, 2024

Goodbye Biosimilars: Coherus Sells Udenyca To Intas For Half A Billion - News & Insights

Dec 04, 2024

S&P 500 Total Return (TCM23) Quote - The Globe and Mail

Dec 04, 2024

Intas Pharma to acquire Udenyca business from Coherus BioSciences - Medical Dialogues

Dec 04, 2024

Dec 03, 2024

Coherus Continues Funding IO Ambitions By Offloading Biosimilars - News & Insights

Dec 03, 2024

TSX Consumer Discretionary Capped Index (TTCD) QuotePress Release - The Globe and Mail

Dec 03, 2024

TSX Composite High Beta Index (TXHB) QuotePress Release - The Globe and Mail

Dec 03, 2024

Redwood City-based Coherus' stock surges after major drug sale - The Business Journals

Dec 03, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Dec 03, 2024

Raleigh pharmaceutical company expands portfolio with $558M deal - The Business Journals

Dec 03, 2024

Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M - BioPharma Dive

Dec 03, 2024

Coherus unloads Udenyca in $558M deal to power immuno-oncology ambitions - FirstWord Pharma

Dec 03, 2024

Coherus shares surge on $558M Udenyca divestiture deal By Investing.com - Investing.com South Africa

Dec 03, 2024

Coherus shares surge on $558M Udenyca divestiture deal - Investing.com

Dec 03, 2024

Unusually active option classes on open December 3rd - TipRanks

Dec 03, 2024

Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth - The Malaysian Reserve

Dec 03, 2024

Why Is Coherus BioSciences Stock Trading Higher On Tuesday? - Inkl

Dec 03, 2024

Coherus Biosciences agrees to divest UDENYCA franchise for up to $558M - TipRanks

Dec 03, 2024

Coherus Bio jumps on deal to divest biosimilar of Amgen's Neulasta - XM

Dec 03, 2024

Coherus BioSciences Shares Rise 22% on Divestiture Agreement With Intas Pharmaceuticals - MarketWatch

Dec 03, 2024

Coherus Biosciences Sells UDENYCA Franchise to Intas - TipRanks

Dec 03, 2024

Coherus BioSciences inks $558.4M deal with Intas Pharmaceuticals; shares rally - Investing.com

Dec 03, 2024

Coherus BioSciences to divest UDENYCA franchise for up to $558.4M (NASDAQ:CHRS) - Seeking Alpha

Dec 03, 2024

Coherus Biosciences to sharpen fcous on immuno-oncology portfolio - TipRanks

Dec 03, 2024

Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. - GlobeNewswire

Dec 03, 2024

Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas - The Bakersfield Californian

Dec 03, 2024

Nov 30, 2024

CHRS (Coherus BioSciences) 50-Day SMA : $0.92 (As of Nov. 30, 2024) - GuruFocus.com

Nov 30, 2024

Nov 28, 2024

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference - The Manila Times

Nov 28, 2024

Nov 27, 2024

Coherus BioSciences to Present at Citi Healthcare Conference's Oncology Panel | CHRS Stock News - StockTitan

Nov 27, 2024

Nov 23, 2024